Nuage Therapeutics (“Nuage”), abiotech company developing a drug discovery engine for small molecule modulators of intrinsically disordered proteins (IDPs), announces today the successful closing of a €12 million Seed financing to support the development of its lead program and validate its pioneering drug discovery platform. The financing round was led by Sofinnova Partners, a leading European venture capital firm in life sciences, and Asabys, together with Nuage, CataloniaBio & HealthTech members, a venture capital firm based in Barcelona and specialized in the healthcare sector, with the participation of Innvierte, an investment program of CDTI Innovación, and BStartup.
Nuage focuses on IDPs driving cancer, which has until recently been considered undruggable due to their lack of structure. The proprietary disruptive technological platform developed by Nuage, born from the convergence of biophysics and chemical biology, leverages the phenomenon of biomolecular condensation. The seed financing will advance the lead program, focused on castration resistant prostate cancer, the second leading cause of death related to cancer in men. It aims to develop a strong pipeline in other untreatable cancer indications.
Judit Anido, CEOof Nuage, comments “IDPs, which perform fundamental cellular functions, are implicated in numerous human diseases. They are perfect targets even though they were historically neglected having been considered undruggable. Our approach has the potential to enabletreatment of a large number of patients with underserved diseases. We are thrilled to attract such strong investors, which reinforces our conviction that Nuage could lead the way in IDP targeting.”
Asabys has supported Nuage since its inception in 2021 and was instrumental to building the company’s business strategy, its team and the investor syndicate. Asabys invests in Nuage through its vehicles Sabadell Asabys and Asabys Top Up Fund. “When we met Nuage’s scientific founders we were impressed with the potential of their science and quickly wanted to help them build the next big thing, providing breakthrough treatments to challenging cancer indications,” explains Clara Campàs, Founding and Managing Partner at Asabys.
Photo : Denes Hnisz (founder), Judit Anido (CEO) Mateusz Biesaga (founder), Xavier Salvatella (founder), Clara Campàs (Managing Partner, Asabys), Maina Bhaman (Partner, Sofinnova Partners), Anna Bellmunt (Associate, Asabys).
Comments